Interleukin 1 (IL1) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Interleukin 1 (IL1) – Pipeline Review, H1 2017’, provides in depth analysis on Interleukin 1 (IL1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Interleukin 1 (IL1)Additionally, the report provides an overview of key players involved in Interleukin 1 (IL1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Metabolic Disorders, Cardiovascular, Oncology, Central Nervous System, Genetic Disorders, Ear Nose Throat Disorders, Gastrointestinal and Genito Urinary System And Sex Hormones under development targeting Interleukin 1 (IL1)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)

The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Anacor Pharmaceuticals Inc

Apexigen Inc

Cell Medica Ltd

Exicure Inc

Immune Response BioPharma Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Orphit SAS

Peptinov SAS

R Pharm

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

TWi Biotechnology Inc

XBiotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interleukin 1 (IL1) - Overview

Interleukin 1 (IL1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Interleukin 1 (IL1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 (IL1) - Companies Involved in Therapeutics Development

AbbVie Inc

Anacor Pharmaceuticals Inc

Apexigen Inc

Cell Medica Ltd

Exicure Inc

Immune Response BioPharma Inc

Novartis AG

Omnitura Therapeutics Inc

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Orphit SAS

Peptinov SAS

R Pharm

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

TWi Biotechnology Inc

XBiotech Inc

Interleukin 1 (IL1) - Drug Profiles

ABT-981 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AC-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AN-4161 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit IL-1 Beta for Epidermolysis Bullosa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-18C3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diacerein CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-2323 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DLX-2681 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-1000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IR-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MABp-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melittin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMN-54 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPV-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-18C3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilonacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RPH-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Interleukin 1 Beta for Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease and Gouty Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOBI-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suramin hexasodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-218C3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Xilonix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ymalzen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interleukin 1 (IL1) - Dormant Products

Interleukin 1 (IL1) - Discontinued Products

Interleukin 1 (IL1) - Product Development Milestones

Featured News & Press Releases

Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting

May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer

Apr 20, 2017: XBiotech Announces Outcome of EMA’s Oral Explanation Meeting

Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex

Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application

Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study

Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa

Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology

Dec 16, 2016: Novartis receives positive CHMP recommendation for Ilaris to treat rare diseases in adults and children called Periodic Fever Syndromes

Dec 07, 2016: XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer

Oct 12, 2016: Xbiotech Announces Successful Completion of EMA GMP Inspection

Oct 01, 2016: Castle Creek Pharmaceuticals Announces Late-Breaking Results at EADV of Phase 2 Topical Diacerein 1% Data in Patients with Epidermolysis Bullosa Simplex

Sep 23, 2016: Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions

Jul 22, 2016: XBiotech Provides Update on Xilonix Phase III Programs in US and EU

Jul 14, 2016: The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress of Gastrointestinal Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Indications, H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Investigation by Universities/Institutes, H1 2017

Products under Investigation by Universities/Institutes, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pipeline by AbbVie Inc, H1 2017

Pipeline by Anacor Pharmaceuticals Inc, H1 2017

Pipeline by Apexigen Inc, H1 2017

Pipeline by Cell Medica Ltd, H1 2017

Pipeline by Exicure Inc, H1 2017

Pipeline by Immune Response BioPharma Inc, H1 2017

Pipeline by Novartis AG, H1 2017

Pipeline by Omnitura Therapeutics Inc, H1 2017

Pipeline by Opsona Therapeutics Ltd, H1 2017

Pipeline by Optimum Therapeutics LLC, H1 2017

Pipeline by Orphit SAS, H1 2017

Pipeline by Peptinov SAS, H1 2017

Pipeline by R Pharm, H1 2017

Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Pipeline by Swedish Orphan Biovitrum AB, H1 2017

Pipeline by TWi Biotechnology Inc, H1 2017

Pipeline by XBiotech Inc, H1 2017

Dormant Products, H1 2017

Dormant Products, H1 2017 (Contd..1), H1 2017

Dormant Products, H1 2017 (Contd..2), H1 2017

Dormant Products, H1 2017 (Contd..3), H1 2017

Dormant Products, H1 2017 (Contd..4), H1 2017

Discontinued Products, H1 2017

Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2017

Number of Products under Development by Therapy Areas, H1 2017

Number of Products under Development by Top 10 Indications, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports